InternationalUSRemember you can easily switch between MIP US and MIP International at any time

SPCs in Europe

  • Lessons on eligibility from recent SPC rulings

    February 23, 2015

    The eligibility criteria for obtaining supplementary protection certificates has been the subject of much debate since the SPC Regulation was introduced in 1992. Laura Reynolds finds some guidance in the latest rulings from the CJEU

  • CJEU gives guidance to patent/SPC owners and importers

    February 13, 2015

    In its latest intervention in the complex world of supplementary protection certificates, the Court of Justice has addressed questions arising from the specific mechanism concerning parallel imports from new EU member states

  • Using patent extension to make up for lost time

    June 02, 2014

    Provisions on patent term extension vary greatly in different jurisdictions. Kathryn D Soulier and Noel E Day provide a guide to the maze of regulations, and advise on how to get maximum protection

  • Judgments leave uncertainty over value of SPCs

    January 31, 2013

    Diana Sternfeld and Nicole Jadeja review the good, the bad and the ugly in recent SPC cases before the Court of Justice of the EU

  • A fillip for the pharmaceutical sector

    December 10, 2012

    Case of the Year: Neurim v UK government

  • Court of Justice rules in favour of Neurim and SPCs

    July 19, 2012

    The Court of Justice of the EU ruled this morning that supplementary protection certificates (SPCs) can be obtained for second medical use patents

  • SPCs in the spotlight: Court of Justice of the EU rules in Neurim on Thursday

    July 17, 2012

    The Court of Justice of the EU will rule in a dispute between Neurim Pharmaceuticals and the UK Intellectual Property Office on Thursday, clarifying whether pharmaceutical companies can obtain supplementary protection certificates (SPCs) for second medical use patents. Here’s the background to the case

  • Court limits power of SPCs

    July 28, 2011

    Products placed on the market in the EU before obtaining a marketing authorisation cannot benefit from supplementary protection certificates, the Court of Justice of the EU said today

  • Advocate General backs negative SPCs

    June 10, 2011

    The Advocate General of the Court of Justice of the EU has recommended that the Court should rule that supplementary protection certificates (SPCs) can be granted where the delay from patent filing to first marketing authorisation is less than five years

  • Questions on SPCs for second medical uses referred

    March 09, 2011

    The Court of Justice of the EU is to clarify whether supplementary protection certificates (SPCs) can be obtained for second medical use patents

  • Call for SPCs to be longer than five years

    October 11, 2010

    The five-year limit on supplementary protection certificates in the EU needs to be extended, said André Bourgouin of Ipsen Pharma last week

Most read articles

Latest Country Updates

Supplements